Cough News and Research RSS Feed - Cough News and Research

State highlights: Caring for Texans injured on-the-job; heroin deaths in Md.; pertussis in Calif.

State highlights: Caring for Texans injured on-the-job; heroin deaths in Md.; pertussis in Calif.

In formerly depressed South Texas, gas flares from the fracking boom can be seen from outer space. While Texas has a Division of Workers' Compensation, it is the only state that doesn't require any private employer to carry workers' compensation insurance or a private equivalent, so more than 500,000 people have no occupational benefits when they get injured at work. That means they often rely on charities or taxpayers to pay for their care (Root, 6/29) [More]
Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal. [More]
Summer offers ideal opportunity to get tonsil removal

Summer offers ideal opportunity to get tonsil removal

Pool pass, sports camp, visiting relatives and getting tonsils removed are all normal activities for children during the summer months. [More]
Denosumab increases bone density for postmenopausal women with osteoporosis

Denosumab increases bone density for postmenopausal women with osteoporosis

Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds. [More]
Researchers study to look at online information available to lung cancer patients

Researchers study to look at online information available to lung cancer patients

Researchers from The University of Manchester have begun a study to look at the online information available to lung cancer patients in an era of diagnosis by google. [More]
Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation. [More]
Studies confirm importance of men seeing physician on regular basis

Studies confirm importance of men seeing physician on regular basis

For many men being a father is about staying strong as they protect and care for their family. Some men see going to the doctor as a weakness or nuisance, but protecting your health is one of the best things a father can do for his family. [More]
Researchers investigate correlation between lower back pain and genes

Researchers investigate correlation between lower back pain and genes

Lower back pain is a broad yet subtle subject. It has widely been associated with early degeneration of the discs of the human spine. [More]
Culture-based tests can help in accurate diagnosis of sore throats

Culture-based tests can help in accurate diagnosis of sore throats

Clinical guidelines conflict on testing teens and adults whose symptoms point to a possible strep throat. [More]
Sanofi and Lilly announces agreement to pursue regulatory approval of Cialis

Sanofi and Lilly announces agreement to pursue regulatory approval of Cialis

Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). [More]
Concise analysis of consumer health market in the UK

Concise analysis of consumer health market in the UK

Reportlinker.com announces that a new market research report is available in its catalogue: Consumer Health in the United Kingdom [More]
AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. [More]
FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). [More]
Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology. [More]
Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration. [More]
COPD patients exposed to warm indoor temperatures have greater disease-related morbidity

COPD patients exposed to warm indoor temperatures have greater disease-related morbidity

If you suffer from COPD, staying cool this summer may provide much more significant benefits than simply feeling more comfortable. A study from researchers at Johns Hopkins University says it may also keep you healthier. [More]
Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D), [More]

Prestige Brands’ net revenues decrease $144.3M to 6.6% in Q4 and FY 2014

Prestige Brands Holdings, Inc. ("the Company") today announced results for the fourth quarter and the fiscal year ended March 31, 2014. [More]
Rates of infant immunization with pertussis-containing vaccine do not increase with epidemic

Rates of infant immunization with pertussis-containing vaccine do not increase with epidemic

Conventional wisdom holds that when the risk of catching a disease is high, people are more likely to get vaccinated to protect themselves. [More]
FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). [More]